Researchers at UCLA have developed a low-cost blood test, MethylScan, that detects multiple cancers and liver diseases by analyzing DNA methylation patterns in cell-free DNA.
Studies demonstrate spatial transcriptomics, 5-base sequencing, and proteomics applications in oncology diagnostics and therapeutic development.
Circulating tumor DNA testing may help predict metastatic risk in muscle-invasive bladder cancer patients opting for bladder-sparing treatment, according to Fox Chase Cancer Center researchers, though additional biomarkers are needed for local recurrence.
Optical genome mapping detected clinically significant genetic variants missed by standard tests in nearly 20% of acute leukemia cases, according to a 200-patient study.
Read More
Seegene unveiled its STAgora real-time data analytics platform and an updated CURECA automated PCR system at ESCMID Global 2026, aiming to enhance infectious disease monitoring through integrated laboratory workflows and aggregated test data.
Read More
The cloud-based system aims to address the bottleneck of translating raw genomic data into actionable information for clinical laboratories.
Read More
The $100 million deal brings an ultra-fast system for respiratory viruses to QuidelOrtho’s point-of-care portfolio.
Read More
The Idylla CDx MSI Test detects microsatellite instability in colorectal cancer tissue in under three hours, supporting therapy selection for eligible patients.
Read More
CellCarta has secured exclusive global rights to deploy Biofidelity’s Aspyre Lung assay in lung cancer clinical trials, streamlining genomic testing for trial sponsors and reducing reliance on multiple vendors.
Read More
A $4 million financing round will support development of a liquid specimen biorepository and expand biopsy catchment pilot programs at medical institutions across the US.
Read More
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
Read More
Presentations at the upcoming annual meeting will focus on AI-based analysis, biomarker prevalence, and therapy development.
Read More
The recommendations focus on using next-generation sequencing to evaluate off-target editing risks and chromosomal integrity.
Read More
Biodesix will present seven abstracts—including two oral sessions—at AACR 2026, highlighting advances in automated myeloid testing, liquid biopsy, and NGS-based cancer monitoring platforms.
Read More
A peer-reviewed study suggests molecular signatures can be identified without invasive uterine sampling using whole-transcriptome sequencing and machine learning.
Read More
The BiliSeq molecular test detected bile duct cancer in 82% of cases—compared to 44% with standard pathology—according to a six-year, multi-institutional study.
Read More
The companion diagnostic can now help identify patients with esophageal or gastroesophageal junction carcinoma who may be eligible for pembrolizumab treatment.
Read More
A retrospective study in Lymphatics reports that CSF liquid biopsy testing delivered clinical impact in 82% of CNS lymphoma cases, resolving diagnoses and informing treatment when standard methods were inconclusive.
Read More